Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novartis

Revenues up 25% on big vaccine boost

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis 1Q10

1Q Revenues: $12.1 billion (+25%)

1Q Earnings: $2.9 billion (+49%)

Comments: The Pharma division had revenues of $7.2 billion (+13%, +7% in constant currency), although top-seller Diovan was down 1% (c.c.) to $1.4 billion. Net sales from the top six emerging markets were up 38% to $1.2 bilion. Vaccine sales accounted for more than $1.0 billion in revenue growth, driven by H1N1 preparations. Sandoz (generic) revenues were up 16% (+9% c.c.) to $2.0 billion; U.S. generics and biosimilars were up 19% c.c.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics